Murray Aitken
Impact in
- Family Practice top 5%
- Medication Adherence and Compliance
- Geriatrics and Gerontology top 5%
- Pharmaceutical Practices and Patient Outcomes
Papers in
-
- Pharmaceutical Economics and Policy 12
- Health Systems, Economic Evaluations, Quality of Life 8
-
- Biotechnology and Related Fields 4
- Co-authors
- Ernst R. Berndt (8 shared papers)Brian Francis (2 shared papers)John Hinde (1 shared paper)Dorothy A. Anderson (1 shared paper)Daniel C. Coster (1 shared paper)David Cutler (2 shared papers)Dorothy Anderson (1 shared paper)John Hinds (1 shared paper)
- Journals
- Health Affairs (3 papers)Drug Discovery Today (2 papers)ESMO Open (1 paper)Nature Reviews Drug Discovery (1 paper)EClinicalMedicine (1 paper)
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Murray Aitken
21 papers receiving 821 citations
Peers
Comparison fields: 5 of 159
- Family Practice 41
- Geriatrics and Gerontology 46
- Economics and Econometrics 263
- Pharmacology 65
- Statistics and Probability 63
Countries citing papers authored by Murray Aitken
This map shows the geographic impact of Murray Aitken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray Aitken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray Aitken more than expected).
Fields of papers citing papers by Murray Aitken
This network shows the impact of papers produced by Murray Aitken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray Aitken. The network helps show where Murray Aitken may publish in the future.
Co-authors
The 25 scholars most cited alongside Murray Aitken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1990 | 220 | |
| 2 | 2012 | 108 | |
| 3 | 2008 | 105 | |
| 4 | 2021 | 86 | |
| 5 | 1990 | 67 | |
| 6 | 2011 | 61 | |
| 7 | 2015 | 58 | |
| 8 | 2016 | 30 | |
| 9 | 2018 | 29 | |
| 10 | 2016 | 29 | |
| 11 | 1974 | 19 | |
| 12 | 2010 | 17 | |
| 13 | 2020 | 17 | |
| 14 | A Prescription for Direct Drug Marketing | 2000 | 8 |
| 15 | 2018 | 7 | |
| 16 | 2013 | 7 | |
| 17 | A License to Cure | 2000 | 6 |
| 18 | 2022 | 6 | |
| 19 | Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation | 2010 | 3 |
| 20 | 2010 | 2 |
About Murray Aitken
Murray Aitken is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health, Pharmacology, Immunology and Molecular Biology, having authored 26 papers that have together received 886 indexed citations. Recurring topics across this work include Pharmaceutical Economics and Policy (12 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers), Pharmaceutical industry and healthcare (5 papers), Biotechnology and Related Fields (4 papers), Biosimilars and Bioanalytical Methods (3 papers), Intellectual Property and Patents (2 papers), Pharmaceutical Practices and Patient Outcomes (2 papers) and Science, Research, and Medicine (2 papers). The work is most often cited by research in Family Practice (41 citations), Geriatrics and Gerontology (46 citations), Economics and Econometrics (263 citations), Pharmacology (65 citations) and Statistics and Probability (63 citations). Murray Aitken has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Ernst R. Berndt, Brian Francis, John Hinde, Dorothy A. Anderson, Daniel C. Coster, David Cutler, Dorothy Anderson, John Hinds, P. A. Lachenbruch and Charlotte Johnston-Webber. Their work appears in journals such as Health Affairs, Drug Discovery Today, ESMO Open, Nature Reviews Drug Discovery and EClinicalMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.